The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2016 | Why novel multiple myeloma drugs are expensive
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives an overview of his talk on the access to novel drugs in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Prof Harousseau argues that it is important to take into consideration, that several new drugs have been approved in recent years and life expectancy for patients has improved. He further discusses the issue of drug prices and the sustainability of healthcare systems as well as the strategies employed by various countries, such as Germany and France, to assess the use of a new drug. According to Prof Harousseau, the question is why these drugs are expensive and he argues that the pricing should be more transparent and fair.
